Summary
Merck & Co., Inc. (MRK) has filed an 8-K report on February 4, 2025, to announce its financial results for the fourth quarter and full year ended 2024. The report incorporates by reference a press release and supplemental information detailing these results. This filing provides investors with key performance indicators and financial condition updates for the company's most recent reporting periods, enabling them to assess the company's operational and financial health and make informed investment decisions. While the specific financial figures are contained within the referenced exhibits, this 8-K serves as the official notification of the release of this crucial data. Investors should consult the attached press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) for a comprehensive understanding of Merck's 2024 performance, including revenue, earnings, and any forward-looking guidance that may have been provided.
Key Highlights
- 1Merck & Co., Inc. (MRK) announced Q4 and full-year 2024 financial results via an 8-K filing on February 4, 2025.
- 2The filing incorporates by reference a press release (Exhibit 99.1) detailing the earnings.
- 3Supplemental financial information not included in the press release is also provided as Exhibit 99.2.
- 4This report allows investors to review Merck's financial performance for the latest reporting periods.
- 5The information provided is furnished under Item 2.02 (Results of Operations and Financial Condition).
- 6Exhibit 104 contains the Cover Page Interactive Data File in Inline XBRL format.